Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity

(2019) Darya Alizadeh et al.   Cancer Immunology Research

CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy

(2019) January Salas-Mckee et al.   Human Vaccines & Immunotherapeutics

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

(2019) Sophia Stock et al.   INTERNATIONAL JOURNAL OF CANCER

Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells

(2019) LEI WANG et al.   CYTOTHERAPY

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy

(2019) Jaco A. C. van Bruggen et al.   BLOOD

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

(2019) TESSA Gargett et al.   CYTOTHERAPY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells

(2019) Wenjie Gong et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Production of CAR T-cells by GMP-grade lentiviral vectors: Latest advances and future prospects

(2019) Mansour Poorebrahim et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics

(2019) Sandhya R. Panch et al.   MOLECULAR THERAPY

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia

(2018) Chiara F. Magnani et al.   HUMAN GENE THERAPY

Influence of retronectin-mediated T cell activation on expansion and phenotype of CD19-specific chimeric antigen receptor T cells

(2018) Sophia Stock et al.   HUMAN GENE THERAPY

T cell senescence and CAR-T cell exhaustion in hematological malignancies

(2018) Dimitri Kasakovski et al.   Journal of Hematology & Oncology

PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells

(2018) Wenting Zheng et al.   LEUKEMIA

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

(2018) Jean-Marc Hoffmann et al.   Frontiers in Immunology

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

(2018) Jeremy S. Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation

(2018) Mark D. Singh et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas

(2018) Carlos A. Ramos et al.   MOLECULAR THERAPY

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

(2018) Joseph A. Fraietta et al.   NATURE

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

(2018) Marco Ruella et al.   NATURE MEDICINE

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of PI3K signaling to improve CAR T cell function

(2018) Wenting Zheng et al.   Oncotarget

Engineering CAR-T Cells for Improved Function Against Solid Tumors

(2018) Michael A. Morgan et al.   Frontiers in Immunology

Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia

(2017) Saeid Taghiloo et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Chimeric antigen receptor transduced T cells: Tuning up for the next generation

(2017) Maria-Luisa Schubert et al.   INTERNATIONAL JOURNAL OF CANCER

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

(2017) Michael Schmueck-Henneresse et al.   JOURNAL OF IMMUNOLOGY

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

(2017) Yinmeng Yang et al.   Science Translational Medicine

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

(2017) Levi J. Rupp et al.   Scientific Reports

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells

(2017) Jacob S. Bowers et al.   Frontiers in Immunology

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy

(2016) Ulrike Mock et al.   CYTOTHERAPY

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation

(2016) Maria-Luisa Schubert et al.   HUMAN GENE THERAPY

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

(2016) Andrea Schietinger et al.   IMMUNITY

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

(2016) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

(2016) Partow Kebriaei et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of memory T cell subsets for adoptive immunotherapy

(2016) Dirk H. Busch et al.   SEMINARS IN IMMUNOLOGY

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

Production of lentiviral vectors

(2016) Otto-Wilhelm Merten et al.   Molecular Therapy-Methods & Clinical Development

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

(2016) Vita Golubovskaya et al.   Cancers

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

(2015) B L Levine   CANCER GENE THERAPY

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

(2015) X Wang et al.   CANCER GENE THERAPY

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2

(2015) Tessa Gargett et al.   CYTOTHERAPY

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy

(2015) Christopher A. Klebanoff et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression

(2015) Kevin J Curran et al.   MOLECULAR THERAPY

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

(2015) Hannah Karlsson et al.   PLoS One

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

(2014) S. Guedan et al.   BLOOD

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

(2014) J. G. Crompton et al.   CANCER RESEARCH

Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy

(2014) David M. Barrett et al.   CYTOTHERAPY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients

(2013) Anna Casati et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

(2013) Saskia JAM Santegoets et al.   Journal of Translational Medicine

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells

(2013) Harjeet Singh et al.   PLoS One

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

(2013) Andre Kunert et al.   Frontiers in Immunology

Role of PI3K/Akt signaling in memory CD8 T cell differentiation

(2013) Eui Ho Kim et al.   Frontiers in Immunology

Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors

(2013) Paul Spear et al.   OncoImmunology

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors

(2012) N. Cieri et al.   BLOOD

Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application

(2012) Ling Zhang et al.   JOURNAL OF IMMUNOTHERAPY

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

(2012) Xiuli Wang et al.   JOURNAL OF IMMUNOTHERAPY

Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor

(2012) Robert PT Somerville et al.   Journal of Translational Medicine

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

(2012) David E. Gilham et al.   TRENDS IN MOLECULAR MEDICINE

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

(2011) H. Singh et al.   CANCER RESEARCH

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation

(2011) David M Kofler et al.   MOLECULAR THERAPY

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

(2010) J. C. Markley et al.   BLOOD

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

(2010) W. Peng et al.   CLINICAL CANCER RESEARCH

Large-scale bioreactor expansion of tumor-infiltrating lymphocytes

(2010) Arian Sadeghi et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

(2009) Luca Gattinoni et al.   NATURE MEDICINE

Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry

(2009) L. Gattinoni et al.   Science Translational Medicine

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

(2008) C. S. Hinrichs et al.   BLOOD

In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method

(2008) S S Yu et al.   CANCER GENE THERAPY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE